Response to: Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ by Gladman
Open Access
- 29 April 2022
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 82 (8), e188
- https://doi.org/10.1136/annrheumdis-2022-222359
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ by Braun and LandewéAnnals Of The Rheumatic Diseases, 2022
- No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?Annals Of The Rheumatic Diseases, 2021
- Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studiesThe Lancet Rheumatology, 2021
- The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in generalAnnals Of The Rheumatic Diseases, 2010
- Classification criteria for psoriatic arthritis: Development of new criteria from a large international studyArthritis & Rheumatism, 2006